RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 20, 2019

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Breast Cancer
Interventions
RADIATION

5 Fraction Stereotactic Body Radiation Therapy

Stereotactic body radiation therapy (SBRT) has gained favor in the treatment of select central nervous system, lung, and abdominal malignancies due to its ability to deliver highly conformal doses of radiotherapy while using sharp dose gradients to deliver comparatively lower doses to the surrounding normal tissue. Utilization of SBRT is more labor intensive than conventional fractionation and requires precise immobilization and localization techniques with daily image guidance with direct physician and physicist oversight for all treatments. While more labor intensive and often utilizing more advanced technologies, SBRT allows the advantage of reducing setup margins compared to conventionally fractionated treatment while being able to shorten overall treatment times due to the ability to safely dose escalate high risk areas

Trial Locations (1)

35233

RECRUITING

University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Varian Medical Systems

INDUSTRY

lead

University of Alabama at Birmingham

OTHER

NCT03643861 - RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI) | Biotech Hunter | Biotech Hunter